WO2011077086A3 - Agents ayant une activité de génération de tissu - Google Patents

Agents ayant une activité de génération de tissu Download PDF

Info

Publication number
WO2011077086A3
WO2011077086A3 PCT/GB2010/002310 GB2010002310W WO2011077086A3 WO 2011077086 A3 WO2011077086 A3 WO 2011077086A3 GB 2010002310 W GB2010002310 W GB 2010002310W WO 2011077086 A3 WO2011077086 A3 WO 2011077086A3
Authority
WO
WIPO (PCT)
Prior art keywords
fraction
emp
lineage
enamel matrix
methods
Prior art date
Application number
PCT/GB2010/002310
Other languages
English (en)
Other versions
WO2011077086A2 (fr
Inventor
Nikolaos Donos
Irwin Olsen
Harsh Devangbhai Amin
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Priority to EP10801674A priority Critical patent/EP2516622A2/fr
Publication of WO2011077086A2 publication Critical patent/WO2011077086A2/fr
Publication of WO2011077086A3 publication Critical patent/WO2011077086A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés d'inhibition, de réalisation ou de stimulation de l'induction de cellules souches dirigée par lignées, les procédés comprenant la mise en contact des cellules souches avec une composition bioactive efficace pour inhiber ou induire leur différenciation dans une lignée de choix, la composition bioactive étant l'un des éléments suivants (a) une fraction de protéine de la matrice amélaire (EMP), ladite fraction étant soit (i) la fraction C de l'EMP, ladite fraction C étant la fraction de l'EMP comprenant des composants d'une taille inférieure à 6 kDa et étant dérivée du gène de l'amélogénine par épissage alternatif et modification post-traductionnelle, soit (ii) la fraction C-dep de l'EMP, la fraction C-dep étant la fraction de l'EMP comprenant des composants d'une taille supérieure à 6 kDa et étant dérivée du gène de l'amélogénine par épissage alternatif et modifications post-traductionnelles, (b) un peptide isolé de ladite fraction, (c) une partie active ou un fragment dudit peptide de (b), (d) un variant de (b) ou (c) présentant une identité de 70 % ou plus avec ceux-ci, (e) un analogue de synthèse ou un dérivé de l'un quelconque des peptides (b) à (d), et la lignée étant choisie dans le groupe constitué par des cellules ostéogéniques, chondrogéniques, angiogéniques, et neurogéniques. La présente invention concerne également des peptides particuliers et des fragments ayant une ou plusieurs des activités pertinentes, et concerne des procédés et compositions apparentés.
PCT/GB2010/002310 2009-12-22 2010-12-21 Agents ayant une activité de génération de tissu WO2011077086A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10801674A EP2516622A2 (fr) 2009-12-22 2010-12-21 Proteines du derive de la matrice d'enamel ayant une activite de generation des tissus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0922438A GB0922438D0 (en) 2009-12-22 2009-12-22 Agents having tissue generative activity
GB0922438.7 2009-12-22

Publications (2)

Publication Number Publication Date
WO2011077086A2 WO2011077086A2 (fr) 2011-06-30
WO2011077086A3 true WO2011077086A3 (fr) 2012-04-05

Family

ID=41717416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/002310 WO2011077086A2 (fr) 2009-12-22 2010-12-21 Agents ayant une activité de génération de tissu

Country Status (3)

Country Link
EP (1) EP2516622A2 (fr)
GB (1) GB0922438D0 (fr)
WO (1) WO2011077086A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013030381B1 (pt) 2011-05-27 2021-10-26 University Of Washington Through Its Center For Commercialization Produto de cuidado oral
WO2014177602A1 (fr) * 2013-04-30 2014-11-06 Straumann Holding Ag Trap 63
EP3355911B1 (fr) * 2015-09-30 2022-11-02 Hadasit Medical Research Services And Development Limited Utilisation de l'amélogénine pleine longueur pour favoriser la croissance ou la régénération nerveuse

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157869A1 (fr) * 2008-06-27 2009-12-30 Straumann Holding Ag Fraction c des dérivés de la matrice amélaire
WO2011073447A1 (fr) * 2009-12-18 2011-06-23 Straumann Holding Ag Emd c-dépleté

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672032A (en) 1983-11-09 1987-06-09 University Of Southern California Dental enamel production
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
SE454480B (sv) 1986-09-25 1988-05-09 Lars Hammarstrom Bindningsinducerande komposition
SE461313B (sv) 1988-03-17 1990-02-05 Biora Ab Bindningsinducerande komposition
US5024841A (en) 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CN1248734C (zh) 1998-02-27 2006-04-05 拜奥拉拜奥爱克斯公司 用于伤口愈合的基质蛋白组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157869A1 (fr) * 2008-06-27 2009-12-30 Straumann Holding Ag Fraction c des dérivés de la matrice amélaire
WO2011073447A1 (fr) * 2009-12-18 2011-06-23 Straumann Holding Ag Emd c-dépleté

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LYNGSTADAAS S P ET AL: "Enamel matrix proteins; old molecules for new applications.", ORTHODONTICS & CRANIOFACIAL RESEARCH AUG 2009 LNKD- PUBMED:19627527, vol. 12, no. 3, August 2009 (2009-08-01), pages 243 - 253, XP002667248, ISSN: 1601-6343 *
MUMULIDU ET AL: "Purification and analysis of a 5kDa component of enamel matrix derivative", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 857, no. 2, 25 September 2007 (2007-09-25), pages 210 - 218, XP022266137, ISSN: 1570-0232, DOI: 10.1016/J.JCHROMB.2007.07.017 *
RAVINDRANATH ET AL: "Enamel formation in vitro in mouse molar explants exposed to amelogenin polypeptides", ARCHIVES OF ORAL BIOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 52, no. 12, 1 November 2007 (2007-11-01), pages 1161 - 1171, XP022324631, ISSN: 0003-9969, DOI: 10.1016/J.ARCHORALBIO.2007.06.008 *
SINGHATANADGIT WEERACHAI ET AL: "Isolation and characterization of stem cell clones from adult human ligament", TISSUE ENGINEERING. PART A, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 15, no. 9, 1 September 2009 (2009-09-01), pages 2625 - 2636, XP009155120, ISSN: 1937-335X *
VEIS ARTHUR ET AL: "Specific amelogenin gene splice products have signaling effects on cells in culture and in implants in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 52, 29 December 2000 (2000-12-29), pages 41263 - 41272, XP002667247, ISSN: 0021-9258 *
WAROTAYANONT ET AL: "Leucine-rich amelogenin peptide induces osteogenesis in mouse embryonic stem cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 367, no. 1, 18 December 2007 (2007-12-18), pages 1 - 6, XP022420105, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.12.048 *

Also Published As

Publication number Publication date
WO2011077086A2 (fr) 2011-06-30
EP2516622A2 (fr) 2012-10-31
GB0922438D0 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
NZ597306A (en) Mesenchymal stem cell differentiation
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2013006486A3 (fr) Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
WO2006056885A3 (fr) Nouveaux peptides igf-i
WO2011036442A3 (fr) Polypeptides et leurs utilisations
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2009065857A3 (fr) Compositions pour la réduction du stress oxydatif et leurs utilisations
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP3533461A3 (fr) Peptides dérivés de prame et compositions immunogènes les comportant
EA201200515A1 (ru) Полипептиды и их применение
WO2017213456A3 (fr) Peptide ayant une activité inhibant la mélanogénèse et composition le comprenant
WO2010141760A3 (fr) Peptides antimicrobiens
WO2009091862A3 (fr) Compositions et procédés pour supprimer des polynucléotides cibles d'un lépidoptère
UA103304C2 (ru) Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
WO2006123097A3 (fr) Element d'expression ameliores
NZ610389A (en) Use of a composition comprising an antimicrobial peptide as a food preservative
WO2008093058A3 (fr) Peptides et leur utilisation
WO2011077086A3 (fr) Agents ayant une activité de génération de tissu
WO2008103378A3 (fr) Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
UA122856C2 (uk) Варіантний інсектицидний ген ахмі115 та способи його застосування
WO2009091860A3 (fr) Compositions et procédés pour la suppression des polynucléotides cibles de la famille aphididae
BR112021018461A2 (pt) Proteínas de fusão, bactérias recombinantes e fragmentos de exospório para saúde da planta
WO2011103666A8 (fr) Modulation des réponses inflammatoires chroniques induites par la cytokine
BRPI1014631A2 (pt) peptídeos e seus usos.
WO2008146116A3 (fr) Composition cosmétique à effet liftant pour soutenir les tissus cutanés relâchés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801674

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010801674

Country of ref document: EP